MX2019010994A - Metodos para tratar enfermedades y trastornos mediados por el complemento. - Google Patents
Metodos para tratar enfermedades y trastornos mediados por el complemento.Info
- Publication number
- MX2019010994A MX2019010994A MX2019010994A MX2019010994A MX2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- complement
- antibody
- individual
- treat diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación suministra métodos para tratar una enfermedad o trastorno mediados por complemento al individuo, y métodos de inhibir la activación del componente C4 del complemento en un individuo en necesidad del mismo. Los métodos comprenden administrar a un individuo un anticuerpo anti-C 1s. Los métodos también comprenden administrar un anticuerpo anti-C1s en una dosis fija, por ejemplo, 5.5 g, 6.5 g, 7.5 g. Los métodos también comprenden administrar una dosis eficaz de un anticuerpo anti-C 1 s al individuo para alcanzar un nivel de suero mínimo de anticuerpo anti-C 1 s para el efecto terapéutico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471190P | 2017-03-14 | 2017-03-14 | |
| US201762553059P | 2017-08-31 | 2017-08-31 | |
| PCT/US2018/022462 WO2018170145A1 (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010994A true MX2019010994A (es) | 2020-12-01 |
Family
ID=61873979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010994A MX2019010994A (es) | 2017-03-14 | 2018-03-14 | Metodos para tratar enfermedades y trastornos mediados por el complemento. |
| MX2025010483A MX2025010483A (es) | 2017-03-14 | 2019-09-13 | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010483A MX2025010483A (es) | 2017-03-14 | 2019-09-13 | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210115116A1 (es) |
| EP (1) | EP3596121A1 (es) |
| JP (3) | JP7293122B2 (es) |
| KR (1) | KR20190128676A (es) |
| CN (1) | CN110753701A (es) |
| AU (2) | AU2018236267B2 (es) |
| BR (1) | BR112019018950A2 (es) |
| CA (1) | CA3055781A1 (es) |
| CR (1) | CR20190468A (es) |
| IL (1) | IL269174B1 (es) |
| MX (2) | MX2019010994A (es) |
| SG (1) | SG11201907583TA (es) |
| TW (2) | TW202513092A (es) |
| WO (1) | WO2018170145A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6538561B2 (ja) | 2012-10-25 | 2019-07-03 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| PT2914291T (pt) | 2012-11-02 | 2022-05-05 | Bioverativ Usa Inc | Anticorpos anti-complemento c1s e suas utilizações |
| ES2938359T3 (es) | 2015-04-06 | 2023-04-10 | Bioverativ Usa Inc | Anticuerpos humanizados anti-C1s y métodos de uso de los mismos |
| FI3525583T3 (fi) | 2016-10-12 | 2025-10-31 | Bioverativ Usa Inc | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä |
| CA3119655A1 (en) | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| IL293363A (en) * | 2019-11-26 | 2022-07-01 | Omeros Corp | Masp-2 inhibitors for use in treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant |
| FI129383B (en) * | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION |
| CA3187866A1 (en) * | 2020-08-06 | 2022-02-10 | Jaime Morales ARIAS | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| CN117241828A (zh) | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | 减少冷凝集素病患者的手术相关溶血 |
| CN117769434A (zh) | 2021-05-20 | 2024-03-26 | 黛安瑟斯医疗运营公司 | 与C1s结合的抗体和其用途 |
| WO2023287573A2 (en) | 2021-07-13 | 2023-01-19 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| AU2023286689A1 (en) * | 2022-06-24 | 2025-02-06 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
| WO2024112734A1 (en) | 2022-11-21 | 2024-05-30 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to c1s and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| PT2914291T (pt) | 2012-11-02 | 2022-05-05 | Bioverativ Usa Inc | Anticorpos anti-complemento c1s e suas utilizações |
| WO2015084999A1 (en) * | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
-
2018
- 2018-03-14 JP JP2019550688A patent/JP7293122B2/ja active Active
- 2018-03-14 KR KR1020197029545A patent/KR20190128676A/ko active Pending
- 2018-03-14 EP EP18715381.2A patent/EP3596121A1/en active Pending
- 2018-03-14 BR BR112019018950-5A patent/BR112019018950A2/pt unknown
- 2018-03-14 TW TW113122096A patent/TW202513092A/zh unknown
- 2018-03-14 SG SG11201907583TA patent/SG11201907583TA/en unknown
- 2018-03-14 MX MX2019010994A patent/MX2019010994A/es unknown
- 2018-03-14 US US16/494,267 patent/US20210115116A1/en not_active Abandoned
- 2018-03-14 CA CA3055781A patent/CA3055781A1/en active Pending
- 2018-03-14 AU AU2018236267A patent/AU2018236267B2/en active Active
- 2018-03-14 CN CN201880029619.1A patent/CN110753701A/zh active Pending
- 2018-03-14 WO PCT/US2018/022462 patent/WO2018170145A1/en not_active Ceased
- 2018-03-14 CR CR20190468A patent/CR20190468A/es unknown
- 2018-03-14 TW TW107108658A patent/TWI848905B/zh active
-
2019
- 2019-09-08 IL IL269174A patent/IL269174B1/en unknown
- 2019-09-13 MX MX2025010483A patent/MX2025010483A/es unknown
-
2023
- 2023-03-01 JP JP2023030606A patent/JP2023071824A/ja active Pending
-
2025
- 2025-01-31 JP JP2025014511A patent/JP2025072437A/ja active Pending
- 2025-06-12 AU AU2025204392A patent/AU2025204392A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201842931A (zh) | 2018-12-16 |
| IL269174A (en) | 2019-11-28 |
| AU2025204392A1 (en) | 2025-07-03 |
| CR20190468A (es) | 2019-12-17 |
| TW202513092A (zh) | 2025-04-01 |
| WO2018170145A1 (en) | 2018-09-20 |
| JP2020511469A (ja) | 2020-04-16 |
| SG11201907583TA (en) | 2019-09-27 |
| TWI848905B (zh) | 2024-07-21 |
| EP3596121A1 (en) | 2020-01-22 |
| KR20190128676A (ko) | 2019-11-18 |
| BR112019018950A2 (pt) | 2020-04-22 |
| IL269174B1 (en) | 2026-01-01 |
| AU2018236267B2 (en) | 2025-03-13 |
| CA3055781A1 (en) | 2018-09-20 |
| CN110753701A (zh) | 2020-02-04 |
| MX2025010483A (es) | 2025-10-01 |
| JP2025072437A (ja) | 2025-05-09 |
| JP7293122B2 (ja) | 2023-06-19 |
| AU2018236267A1 (en) | 2019-09-26 |
| US20210115116A1 (en) | 2021-04-22 |
| JP2023071824A (ja) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX2019006177A (es) | Metodos para tratar afecciones inflamatorias. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| MX2018010852A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2. | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| MX376077B (es) | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| CL2021001389A1 (es) | Formulaciones en cápsula | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| MX2020003682A (es) | Metodos para tratar enfermedades asociadas con ciliopatias. | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| MX375924B (es) | Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo. |